NR4A1 and breast cancer: Patients with early stage hormone receptor positive (HR +) breast cancers have a risk of distant recurrence that remains high over a prolonged period, with approximately 50% of recurrences occurring more than 5 years after diagnosis despite optimal locoregional and standard adjuvant systemic therapies [1–3].